All In Biotech

NDA 050580 · Labs Delbert

Azactam

Aztreonam · Injection · Monobactam Antibacterial

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Apr 16, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1986

Dec 31, 1986

Approved uses

2

Original approval plus efficacy supplements

Registered trials

66

34 Phase 3, 9 recruiting

FAERS reports

2,727

2,510 serious, 590 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 15, 2025.

INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of AZACTAM (aztreonam for injection, USP) and other antibacterial drugs, AZACTAM should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. AZACTAM is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli , Klebsiella pneumoniae , Proteus mirabilis , Pseudomonas aeruginosa , Enterobacter cloacae , Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Haemophilus influenzae , Proteus mirabilis , Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Proteus mirabilis *, Serratia marcescens *, and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli , Proteus mirabilis , Serratia marcescens , Enterobacter species, Pseudomonas aeruginosa , Klebsiella pneumoniae , and Citrobacter species*. Intra-abdominal Infections , including peritonitis caused by Escherichia coli , Klebsiella species including K....

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 1, 1996 Supplement 8 · Efficacy
  • Dec 31, 1986 Original approval · Type 1 - New Molecular Entity · priority review Review
3 products under this application
  • AZACTAM · AZTREONAM 1GM/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
  • AZACTAM · AZTREONAM 2GM/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
  • AZACTAM · AZTREONAM 500MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Aztreonam" as an intervention, any sponsor and status, largest first.

All 66 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use194
  • pyrexia176
  • eosinophilia160
  • drug ineffective152
  • dyspnoea134
  • rash131
  • acute kidney injury127
  • drug reaction with eosinophilia and systemic symptoms120
  • thrombocytopenia117
  • septic shock103
  • condition aggravated101
  • renal failure98

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200442
200546
200651
200737
200847
200950
201050
201185
201278
201375
2014124
2015104
2016148
2017139
2018158
2019206
2020207
2021264
2022161
2023183
2024215
2025149
2026108

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Azactam (Aztreonam)

2024 spending

$107K

Beneficiaries

133

255 claims

Per beneficiary

$803

$6.30 per unit

View as table
YearSpending
2020$309,078
2021$338,839
2022$218,231
2023$207,452
2024$106,778

Part B: Azactam* (Aztreonam*) · HCPCS J0457

2024 spending

$117K

Beneficiaries

981

1,752 claims

Per beneficiary

$119

2024 ASP limit $2.30 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$13,640
2024$116,665

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 292 on PubMed

Sponsor: Labs Delbert

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.